Navigation Links
Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
Date:5/22/2008

LAS VEGAS, May 22 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has entered into an agreement with Dr. H. Christopher Moore to be the sponsor and general partner of ProDerm Limited Partnership (PDLP) which will fund a minimum of $1 million and up to $10 million of the clinical development for CVBT's wound healing drug candidate.

"I am extremely impressed with CVBT's wound healing drug, which I believe has the potential to treat patients for diabetic ulcers and venous stasis leg wounds better than any of the current products on the market. The active pharmaceutical ingredient (API) is truly remarkable," said Dr. Moore.

PDLP will engage CVBT in a development agreement to conduct wound healing clinical trials. CVBT will pay a royalty to PDLP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of twenty times (20x) the funded amount of the development agreement in exchange for the intellectual property created. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of PDLP a "Put" to Mr. Montano for their interest in CDCP equal to 200% of their investment in PDLP less distributions paid from PDLP commencing 36 months and ending 60 months after their investment in PDLP.

"These clinical partnerships are very important to the timely development of CVBT's drug candidates. The ability to access the necessary funding for CVBT's FDA clinical trials through clinical partnerships during these uncertain times for the capital markets gives us the ability to move forward with our planned clinical development schedule," said Mr. Montano.

"CVBT now has two clinical partnerships in place supporting its trials through development agreements. The relative cost of capital and the minimal dilution to existing shareholders makes this financing vehicle an attractive alternative to selling equity and placing deb
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
6. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:10/1/2014)... October 01, 2014 After undergoing a ... chamber of commerce to join, Living Well Assisted Living ... Commerce in Marin County, the home of its headquarters. ... the moment, and the thought of adding one more ... to keep looking for the right chamber to join ...
(Date:10/1/2014)... Angeles, CA (PRWEB) October 01, 2014 ... debut documentary film, "Beautiful Births", emerging filmmaker Jacqui Blue ... help other women discover the truth about natural birth. ... from people all over the world and has been ... birth. Many of the topics highlighted in the film ...
(Date:10/1/2014)... 2014 Indosoft, Inc., a leading provider of ... it has added support for Sangoma Lyra ... Indosoft have a history of bringing innovative products to ... offers a significant benefit to those using Asterisk as a ... available to users of Q-Suite. , In the past decades, ...
(Date:10/1/2014)... QueenBeeTickets.com is giving music fans the opportunity to purchase ... tour, which has him traveling from November 19 until December ... to view the selection of presale tickets available at ... to come out on October 14, and the tour in ... tickets are available for shows that will take place in ...
(Date:9/30/2014)... one third of medical and nursing students in developing ... own countries after graduation, while less than one fifth ... they are needed most, according to a new study. ... driving the current outbreak of Ebola in western Africa. ... three of the world,s poorest countries (Guinea, Sierra Leone ...
Breaking Medicine News(10 mins):Health News:Living Well Joins San Rafael Chamber of Commerce 2Health News:Living Well Joins San Rafael Chamber of Commerce 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:Bob Seger Presale Tickets: QueenBeeTickets.com Delights Fans with Discounted Tickets for All 20 Stops on Seger’s “Ride Out” Tour with The Silver Bullet Band 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3
... , , EXTON, Pa., ... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that the ... of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) ... life-threatening bacterial infections of the gastrointestinal (GI) tract, Clostridium difficile ...
... ... versus Goliath struggle raging in the West, joins the stellar line-up at the ... and in Los Angeles (August 7 - 13). The film will also air ... Impact series on Planet Green, a network of Discovery Communications.,Split Estate maps a ...
... , , , ... (Nasdaq: CLRT ), a premier anatomic pathology and molecular testing ... results for the second quarter and six months ended June 30, 2009. ... second quarter of 2009 versus the second quarter of 2008, and a ...
... EAST RUTHERFORD, N.J., Aug. 4 Cambrex Corporation (NYSE: CBM ) ... Highlights , , Sales ... Reported sales declined by 9.8% for the quarter. , EBITDA ... year (see attached table). , Debt, net of cash was ...
... and MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ - Covidien (NYSE: ... products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug ... Drug Administration (FDA) has set a new action date ... Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November ...
... , WALTHAM, Mass., Aug. 4 Inverness ... leader in enabling individuals to take charge of their health ... management, today announced that it intends to offer $150 million ... of the notes will be guaranteed by certain of Inverness, ...
Cached Medicine News:Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 2Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 3Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 4Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:Cambrex Reports Second Quarter 2009 Results 2Health News:Cambrex Reports Second Quarter 2009 Results 3Health News:Cambrex Reports Second Quarter 2009 Results 4Health News:Cambrex Reports Second Quarter 2009 Results 5Health News:Cambrex Reports Second Quarter 2009 Results 6Health News:Cambrex Reports Second Quarter 2009 Results 7Health News:Cambrex Reports Second Quarter 2009 Results 8Health News:Cambrex Reports Second Quarter 2009 Results 9Health News:Cambrex Reports Second Quarter 2009 Results 10Health News:Cambrex Reports Second Quarter 2009 Results 11Health News:Cambrex Reports Second Quarter 2009 Results 12Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes 2
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: